Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07357610

An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants

This study is an open-label, fixed-sequence, two-period Phase 1 clinical trial in healthy adult Chinese participants with a total of 3 cohorts, 16-20 healthy adult Chinese participants are planned to be enrolled in each cohort.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Healthy Adult Participants

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Shandong University of Qilu Hospital

Jinan, Shandong, 250100, China

Location status: Recruiting

Location contact

Rui Zhang, PHD

CONTACT

Rui Zhang, PHD

PRINCIPAL_INVESTIGATOR

Wei Zhao, PHD

CONTACT

[email protected]

+86 0531-82169023

Wei Zhao, PHD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The participant fully understand the test content, process and possible adverse reactions, voluntarily sign informed consent, have good communication with the researchers, and can complete all the test procedures in accordance with the protocol.
  • Cohorts 1 and 2: healthy male and female participants aged ≥ 18 and ≤ 55 years; Cohort 3: healthy male participants aged ≥ 18 and ≤ 55 years.
  • Male participants weigh ≥ 50 kg; Female participants weigh ≥ 45 kg; Body mass index ≥ 19 kg/m2 and ≤ 26 kg/m2.
  • Cohorts 1 and 2: all female participants of childbearing potential and male participants with partners of women of childbearing potential agree to take recognized effective contraceptive measures during the study period and within 6 months after the last dose of the investigational product, starting from signing the informed consent; Cohort 3: male participants with partners of women of childbearing potential agree to take recognized effective contraceptive measures during the study period and within 6 months after the last dose of the investigational product, starting from signing the informed consent.

Exclusion criteria

Past/Ongoing Medical History

  • Neurological/psychiatric, respiratory, cardiovascular, gastrointestinal, urinary, hematological and lymphatic, endocrine, skeletal-muscular disorders, especially hepatic and renal insufficiency, or any other disease and condition that may affect the results of the study or the safety of the participants.
  • History of dysphagia or any gastrointestinal disorder affecting drug absorption.
  • Presence of risk factors for Torsade de Pointes (e.g., history of heart failure, hypokalemia, family history of QT prolongation syndrome), or other clinically significant abnormalities judged by the study doctor (including but not limited to: complete left bundle branch block; right bundle branch block; first-, second-, or third-degree heart block; sick sinus syndrome or previous history of myocardial infarction).
  • History of active or latent tuberculosis.
  • History of malignancy. Except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, or stage I uterine cancer (disease-free interval of at least 5 years).
  • Any acute or chronic condition that, in the opinion of the investigator, would limit the ability of participants to complete and/or participate in this clinical study.

Surgical history • Those who have undergone major surgery within 6 months prior to screening or are scheduled to undergo surgery during the study and are judged by the investigator to be inappropriate for enrollment.

History of allergy

  • Allergic to the study drug or any component of the study drug, with a history of specific allergies (asthma, urticaria, eczema, etc.) or allergic constitution (e.g., those allergic to two or more drugs, food such as milk and pollen).

Medication history

  • Use of hormone replacement therapy or selective estrogen mediators within 1 year prior to screening.
  • Use or planned use of any drug/product within 4 weeks prior to screening that would alter the process of drug absorption, metabolism, or elimination.
  • Use of any prescription drugs/products within 2 weeks prior to screening or over-the-counter medications (including vitamins, minerals, phytotherapies, herbal and botanical preparations) within 1 week prior to screening.

Screening or Baseline Examinations

  • Laboratory tests, physical examination, vital signs, 12-lead electrocardiogram, chest anterolateral film, abdominal B-ultrasound results were abnormal and clinically significant as judged by the investigator.
  • Screening (mean) or baseline ECG heart rate < 60 beats/min or > 100 beats/min, QTcF interval > 450 ms.
  • Women of childbearing potential who have a positive pregnancy test or are pregnant or lactating (see Appendix 1 for definitions of women of non-childbearing potential).
  • Positive tests for hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV) antibody, treponema pallidum antibody.
  • History of drug abuse or positive drug abuse screening.
  • Regular drinkers, i.e., on average, more than 2 units of alcohol per day (1 unit = 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) within 3 months prior to screening or during the screening period to the first dose; Or alcohol breath test positive.
  • Those who smoke more than 5 cigarettes per day within 3 months prior to screening or who cannot quit during the trial.
  • Participation in any drug clinical trial as a participant and taking study drug or medical device intervention within 3 months prior to screening.
  • Consumption of grapefruit or grapefruit-related citrus (e.g., grapefruit) fruit or juice within 1 week prior to screening, or use of alcoholic or caffeinated food or beverages within 72 h prior to screening.
  • Those who have special requirements for diet and cannot comply with the diet provided and corresponding regulations.
  • Those who have difficulty in venous blood collection, or have a history of fainting blood and needle sickness, or who cannot tolerate venous indwelling needle blood collection.
  • Those who have donated blood or lost more than 200 mL of blood within 3 months prior to screening, or have received blood transfusions or blood products within 2 months.
  • Participants have other conditions that are not suitable for participation in the study, or participants may not be able to complete the study for other reasons

Treatment and study plan

SIM0270

Drug

oral

Itraconazole

Drug

oral

Rifampin

Drug

oral

midazolam

Drug

oral

Primary outcomes

  1. Maximum observed concentration (Cmax) of SIM0270

    Time frame: Day 1-Day 13, Day 16-Day 30

    To determine the effect of itraconazole on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  2. Area under concentration curve from time 0 to the last quantifiable concentration (AUC0-t) of SIM0270

    Time frame: Day 1-Day 13, Day 16-Day 30

    To determine the effect of itraconazole on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  3. Area under concentration-time curve from time 0 to infinity (AUC0-∞) of SIM0270

    Time frame: Day 1-Day 13, Day 16-Day 30

    To determine the effect of itraconazole on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  4. Area under concentration-time curve from time 0 to tau (AUC0-tau) of SIM0270

    Time frame: Day 1-Day 13, Day 16-Day 30

    To determine the effect of itraconazole on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  5. Terminal half-life（t1/2）of SIM0270

    Time frame: Day 1-Day 13, Day 16-Day 30

    To determine the effect of itraconazole on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  6. Maximum observed concentration (Cmax) of SIM0270

    Time frame: Day 1-Day 13, Day 20-Day 32

    To determine the effect of rifampicin on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  7. Area under concentration curve from time 0 to the last quantifiable concentration (AUC0-t) of SIM0270

    Time frame: Day 1-Day 13, Day 20-Day 32

    To determine the effect of rifampicin on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  8. Area under concentration-time curve from time 0 to infinity (AUC0-∞) of SIM0270

    Time frame: Day 1-Day 13, Day 20-Day 32

    To determine the effect of rifampicin on the PK of a single dose of SIM0270 in Chinese healthy adult participants

  9. Terminal half-life（t1/2）of SIM0270

    Time frame: Day 1-Day 13, Day 20-Day 32

    To determine the effect of rifampicin on the PK of a single dose of SIM0270 in Chinese healthy adult participants.

  10. Maximum observed concentration (Cmax) of midazolam

    Time frame: Day 1-Day 2, Day 11-Day 13

    To determine the effect of SIM0270 on the PK of a single dose of midazolam in Chinese healthy adult male participants.

  11. Area under concentration curve from time 0 to the last quantifiable concentration (AUC0-t) of Midazolam

    Time frame: Day 1-Day 2, Day 11-Day 13

    To determine the effect of SIM0270 on the PK of a single dose of midazolam in Chinese healthy adult male participants.

  12. Area under concentration-time curve from time 0 to infinity (AUC0-∞) of Midazolam

    Time frame: Day 1-Day 2, Day 11-Day 13

    To determine the effect of SIM0270 on the PK of a single dose of midazolam in Chinese healthy adult male participants.

  13. Terminal half-life（t1/2）of midazolam

    Time frame: Day 1-Day 2, Day 11-Day 13

    To determine the effect of SIM0270 on the PK of a single dose of midazolam in Chinese healthy adult male participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Qiuping Huang, Master

CONTACT

[email protected]

86+15060083948

Sponsors and collaborators

Lead sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.

Industry

Registry information

Acronym: SIM0270-104

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 22, 2026
Registry last updated
Jan 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.